Issues
-
Cover Image
Cover Image
Gliomas are marked by a diffuse pattern of tumor cell invasion into the cerebrum, which contributes to poor outcomes in patients with advanced disease. The cover depicts a cross-section of a cerebral organoid co-cultured with GFP-labeled U87 glioma cell spheroids stably expressing adaptor protein ShcD and receptor tyrosine kinase Tie2. The glioma cells (green) can be observed invading the organoid model, stained with neuronal marker Tuj1 (magenta). The authors show that interactions between ShcD and Tie2 trigger signaling events within glioma cells that promote invasiveness and could be targeted for therapeutic benefit. For more information, see the article on page 757. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Minireview
Perspective
Cancer Genes and Networks
Functional Hierarchy and Cooperation of EMT Master Transcription Factors in Breast Cancer Metastasis
Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids
Cancer “-omics”
Colorectal Cancer–Derived CAT1-Positive Extracellular Vesicles Alter Nitric Oxide Metabolism in Endothelial Cells and Promote Angiogenesis
Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions
Cell Fate Decisions
Palbociclib Renders Human Papilloma Virus–Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax
Genome Maintenance
Signal Transduction and Functional Imaging
Preclinical Evaluation of Gilteritinib on NPM1-ALK–Driven Anaplastic Large Cell Lymphoma Cells
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.